MedTrace Logo

Effects of Medical Treatment of ICAS With Hemodynamic Disorders Based on MR-FFR

NCT06196398 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2024-01-09

No results posted yet for this study

Summary

This multicenter prospective cohort study aims to compare the difference in the effects of medical treatment within 1 year between the two groups of ICAS patients divided hemodynamically by Magnetic Resonance Fractional Flow Reserve. PC MRA will be applied for FFR measurement. The primary outcome is the composite of ischemic stroke or death related to the qualifying artery territory for 1 year.

Conditions

  • Stroke, Ischemic
  • Intracranial Atherosclerosis

Interventions

DRUG

Standard Medical Treatment on the basis of anti-platelet therapy

1. Anti-platelet therapy: aspirin 75mg+clopidogrel 100mg will be applied for patients with severe ICAS stenosis (70%-90%) suffering stroke or TIA within 30 days. After 90 days, single anti-platelet therapy will be continued. 2. Intensive statin therapy: Statins with high doses 3. Blood pressure: below 140/90mmHg 4. LDL: less than 1.81mmol/L(70mg/dl) 5. Fasting blood glucose controlled to 5.9mmol/L, and glycosylated hemoglobin A1c reduced to less than 7% 6. Cigarette and alcohol quitting 7. Oral anticoagulants for atrial fibrillation

Sponsors & Collaborators

  • National Key Research and Development Project, China

    collaborator UNKNOWN

  • Xuanwu Hospital, Beijing

    lead OTHER

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06196398 on ClinicalTrials.gov